Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PGG glucan - Biothera

Drug Profile

PGG glucan - Biothera

Alternative Names: B-glucan PGG; BTH-1677; Imprime PGG; Soluble beta glucan - Biothera

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biothera
  • Developer Biothera; Dana-Farber Cancer Institute; Mayo Clinic; Merck Sharp & Dohme
  • Class Antibacterials; Antineoplastics; Beta Glucans
  • Mechanism of Action Dectin 1 stimulants; Fc gamma receptor IIA modulators; Immunostimulants; Macrophage 1 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase II Breast cancer; Head and neck cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer
  • Phase I/II Chronic lymphocytic leukaemia
  • Suspended Infections
  • No development reported Follicular lymphoma; Pancreatic cancer
  • Discontinued Myelosuppression; Stem cell mobilisation

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for research development in Follicular lymphoma(Combination therapy) in USA (IV)
  • 31 Jul 2019 Biothera and Dana-Farber Cancer Institute complete the phase-II trial in Non-Hodgkin's lymphoma (Second-line therapy or greater, Combination therapy) in USA (IV) (NCT02086175)
  • 01 Jun 2019 Updated efficacy and adverse events data from the phase II IMPRIME 1 trial in Breast cancer presented at the Annual Meeting of American Society of Clinical Oncology (ASCO -2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top